IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Bellevue Group AG

Bellevue Group AG lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.2% in the third quarter, Holdings Channel.com reports. The firm owned 91,279 shares of the company’s stock after selling 2,079 shares during the period. Bellevue Group AG’s holdings in IDEXX Laboratories were worth $46,116,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Cobblestone Capital Advisors LLC NY boosted its stake in shares of IDEXX Laboratories by 1.0% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 24,484 shares of the company’s stock valued at $12,370,000 after buying an additional 244 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its position in shares of IDEXX Laboratories by 151.3% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 85,927 shares of the company’s stock worth $43,412,000 after purchasing an additional 51,728 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of IDEXX Laboratories by 20.5% in the 3rd quarter. Verition Fund Management LLC now owns 6,508 shares of the company’s stock valued at $3,288,000 after purchasing an additional 1,108 shares in the last quarter. Icon Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth about $264,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in IDEXX Laboratories by 0.9% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 52,744 shares of the company’s stock worth $26,650,000 after buying an additional 448 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of several recent research reports. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Finally, Piper Sandler restated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Stock Down 0.0 %

IDXX opened at $421.75 on Friday. The stock’s 50 day moving average price is $451.91 and its 200 day moving average price is $477.81. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock has a market cap of $34.54 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $2.53 earnings per share. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.